Västra Hamnen Market Focus: Bioextrax: The American start-up cancels deal
- Limited effect on short-term earnings, higher perceived risk
- Bioextrax signs MoU with Chematur Engineering
- We have adjusted the fair value to SEK 7.60 (10.50) per share
In September 2023, an American start-up company extended the license agreement with Bioextrax regarding production of PHA. In January 2024, the American company had to terminate the contract due to financial issues. Hence, our model suggests a fair value of SEK 7.60 per share.
The initial research report is available here.